Literature DB >> 31848078

Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort.

Hannes Jansson1, Martin Cornillet2, Niklas K Björkström2, Christian Sturesson3, Ernesto Sparrelid3.   

Abstract

INTRODUCTION: Established preoperative prognostic factors for risk stratification of patients with biliary tract cancer (BTC) are lacking. A prognostic value of the inflammation-based Glasgow Prognostic Score (GPS) and Modified Glasgow Prognostic Score (mGPS) in BTC has been indicated in several Eastern cohorts. We sought to validate and compare the prognostic value of the GPS and the mGPS for overall survival (OS), in a large Western cohort of patients with BTC.
MATERIAL AND METHODS: We performed a retrospective single-center study for the period 2009 until 2017. 216 consecutive patients that underwent surgical exploration with a diagnosis of perihilar cholangiocarcinoma (PHCC), intrahepatic cholangiocarcinoma (IHCC), or gallbladder cancer (GBC) were assessed. GPS and mGPS were calculated where both CRP and albumin were measured pre-operatively (n = 168/216). Survival was analyzed by Kaplan-Meier estimate and uni-/multivariate Cox regression.
RESULTS: GPS and mGPS were negatively associated with survival (p < 0.001/p < 0.001), and the association was significant in all three subgroups. GPS, but not the mGPS, identified an intermediate risk group: with GPS = 1 having better OS than GPS = 2 (p = 0.003), but worse OS than GPS = 0 (p = 0.008). In multivariate analyses of resected patients, GPS (p = 0.001) and mGPS (p = 0.03) remained significant predictors of survival, independent of postoperatively available risk factors.
CONCLUSIONS: Preoperative GPS and mGPS are independent prognostic factors in BTC. The association to OS was shown in all patients undergoing exploration, in resected patients only, and in both cholangiocarcinoma and gallbladder cancer. Furthermore, GPS - which weights hypoalbuminemia higher - could identify an intermediate risk group.
Copyright © 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Biliary tract cancer; Glasgow prognostic score; Preoperative; Prognostic factor; Risk stratification; Systemic inflammatory response

Year:  2019        PMID: 31848078     DOI: 10.1016/j.ejso.2019.12.008

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  7 in total

1.  Relationship of immunonutritional factor with changes in liver volume after portal vein embolization.

Authors:  Atsushi Nanashima; Yukinori Tanoue; Koichi Yano; Masahide Hiyoshi; Naoya Imamura; Takeomi Hamada; Kengo Kai; Eiji Kitamura; Yasuto Suzuki; Kousei Tahira; Fumiya Kawano; Takeshi Nagayasu
Journal:  Surg Open Sci       Date:  2022-05-28

2.  Prognostic significance of preoperative systemic inflammation response index in newly diagnosed glioblastoma patients underwent gross total resection: a propensity score matching analysis.

Authors:  Zhihao Wang; Junhong Li; Yunbo Yuan; Tengfei Li; Mingrong Zuo; Yanhui Liu
Journal:  World J Surg Oncol       Date:  2022-04-29       Impact factor: 3.253

3.  Evaluation of Preoperative Inflammation-Based Prognostic Scores in Patients With Intrahepatic Cholangiocarcinoma: A Multicenter Cohort Study.

Authors:  Chaobin He; Chongyu Zhao; Jiawei Lu; Xin Huang; Cheng Chen; Xiaojun Lin
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

4.  Lymphocyte to C-reactive protein ratio predicts long-term outcomes for patients with lower rectal cancer.

Authors:  Masaaki Nishi; Mistuo Shimada; Takuya Tokunaga; Jun Higashijima; Kozo Yoshikawa; Hideya Kashihara; Chie Takasu; Daichi Ishikawa; Yuma Wada; Shohei Eto; Toshiaki Yoshimoto
Journal:  World J Surg Oncol       Date:  2021-07-06       Impact factor: 2.754

5.  The prognostic value of sarcopenia combined with preoperative fibrinogen-albumin ratio in patients with intrahepatic cholangiocarcinoma after surgery: A multicenter, prospective study.

Authors:  Haitao Yu; Mingxun Wang; Yi Wang; Jinhuan Yang; Liming Deng; Wenming Bao; Bangjie He; Zixia Lin; Ziyan Chen; Kaiyu Chen; Baofu Zhang; Fangting Liu; Zhengping Yu; Longyun Ye; Bin Jin; Gang Chen
Journal:  Cancer Med       Date:  2021-06-08       Impact factor: 4.452

6.  Development and Validation of a Prognostic Nomogram Based on the Systemic Immune-Inflammation Index for Resectable Gallbladder Cancer to Predict Survival and Chemotherapy Benefit.

Authors:  Lin Li; Tai Ren; Ke Liu; Mao-Lan Li; Ya-Jun Geng; Yang Yang; Huai-Feng Li; Xue-Chuan Li; Run-Fa Bao; Yi-Jun Shu; Hao Weng; Wei Gong; Wan Yee Lau; Xiang-Song Wu; Ying-Bin Liu
Journal:  Front Oncol       Date:  2021-06-29       Impact factor: 6.244

7.  Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma.

Authors:  Wei Chen; Boer Shan; Shuling Zhou; Huijuan Yang; Shuang Ye
Journal:  BMC Cancer       Date:  2022-01-21       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.